Literature DB >> 9633519

Disruption of the lama2 gene in embryonic stem cells: laminin alpha 2 is necessary for sustenance of mature muscle cells.

W Kuang1, H Xu, P H Vachon, E Engvall.   

Abstract

Mutations in the gene coding for the alpha 2 chain of laminin-2 and -4 (merosin) cause a severe form of congenital muscular dystrophy in humans and mice. To establish a defined model for in vitro and in vivo studies of the role of laminin alpha 2/merosin in development and cell and tissue function, we generated several lines of mutant embryonic stem (ES) cell with disruption of the laminin alpha 2 chain gene. We find that homozygous mutant ES cells differentiate normally in vitro, giving rise to cardiomyocytes, myotubes, and smooth muscle cells in addition to many other cell types. However, the myotubes that are formed are unstable. They detach, collapse, and degenerate, a process which is initiated at the appearance of the mature, contractile phenotype of the cells. We propose that the detachment and death of contracting myotubes in vitro has its counterpart in vivo and that contraction-induced myofiber damage, along with the lack of survival cues provided by laminin alpha 2/merosin, is a significant contribution to muscle degeneration in merosin-deficient muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633519     DOI: 10.1006/excr.1998.4025

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  18 in total

1.  The C-terminal region of laminin beta chains modulates the integrin binding affinities of laminins.

Authors:  Yukimasa Taniguchi; Hiroyuki Ido; Noriko Sanzen; Maria Hayashi; Ryoko Sato-Nishiuchi; Sugiko Futaki; Kiyotoshi Sekiguchi
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

2.  Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality.

Authors:  Zhi-Fang Li; G Diane Shelton; Eva Engvall
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

3.  Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy.

Authors:  Jachinta E Rooney; Praveen B Gurpur; Zipora Yablonka-Reuveni; Dean J Burkin
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 4.  The role of laminins in the organization and function of neuromuscular junctions.

Authors:  Robert S Rogers; Hiroshi Nishimune
Journal:  Matrix Biol       Date:  2016-09-07       Impact factor: 11.583

5.  Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.

Authors:  Rui Xu; Kumaran Chandrasekharan; Jung Hae Yoon; Marybeth Camboni; Paul T Martin
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 6.  Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.

Authors:  Peter D Yurchenco; Karen K McKee; Judith R Reinhard; Markus A Rüegg
Journal:  Matrix Biol       Date:  2017-11-27       Impact factor: 11.583

7.  Laminin-2 stimulates the proliferation of epithelial cells in a conjunctival epithelial cell line.

Authors:  J Dowgiert; G Sosne; M Kurpakus-Wheater
Journal:  Cell Prolif       Date:  2004-04       Impact factor: 6.831

8.  Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A).

Authors:  Sarina Meinen; Shuo Lin; Markus A Ruegg
Journal:  Skelet Muscle       Date:  2012-09-03       Impact factor: 4.912

9.  Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies.

Authors:  Kinga I Gawlik; Madeleine Durbeej
Journal:  Skelet Muscle       Date:  2011-03-01       Impact factor: 4.912

10.  Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice.

Authors:  Sarina Meinen; Shuo Lin; Raphael Thurnherr; Michael Erb; Thomas Meier; Markus A Rüegg
Journal:  EMBO Mol Med       Date:  2011-06-15       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.